Roche’s Tecentriq Improves Survival in Ineligible NSCLC Patients

a professor at UCL, stated that these results are significant because they provide evidence that Tecentriq can be a viable treatment option for NSCLC patients who cannot tolerate platinum-based chemotherapy. Tecentriq is an immune checkpoint inhibitor that works by blocking the PD-L1 protein on cancer cells, allowing the body's immune system to recognize and attack the tumor. It has already been..